sulindac

Summary

Summary: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.

Top Publications

  1. pmc Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage
    Kasirajan Ayyanathan
    Center for Molecular Biology and Biotechnology, Charles E Schmidt College of Science, Florida Atlantic University, Jupiter, Florida, United States of America
    PLoS ONE 7:e39949. 2012
  2. pmc NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling
    Hu Zhou
    Institute for Biomedical Research, Xiamen University, Xiamen, Fujian 361005, China
    Cancer Cell 17:560-73. 2010
  3. pmc Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs
    X Li
    Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA
    Oncogene 31:4979-86. 2012
  4. ncbi The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15
    Jong Sik Kim
    Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, MD E4 09, P O Box 12233, 111 TW Alexander Drive, Research Triangle Park, NC 27709, USA
    Mol Cancer Ther 4:487-93. 2005
  5. pmc Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California, USA
    Cancer Prev Res (Phila) 1:32-8. 2008
  6. pmc Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer
    Ka Wing Cheng
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY, USA
    Int J Oncol 41:1199-203. 2012
  7. ncbi Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis
    Frank G Bottone
    Laboratory of Molecular Carcinogenesis, the Laboratory of Computational Biology and Risk Analysis, and National Center for Toxicogenomics, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
    J Biol Chem 278:25790-801. 2003
  8. ncbi The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway
    Raminder Singh
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Apoptosis 16:889-901. 2011
  9. ncbi Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons
    Amichand Dairam
    Faculty of Pharmacy, Rhodes University, P O Box 94, Grahamstown 6140, South Africa
    Metab Brain Dis 21:221-33. 2006
  10. ncbi High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors
    Anika Hansmann
    Department of General Surgery and Traumatology, Heinrich Heine University, Duesseldorf, Germany
    Cancer 100:612-20. 2004

Detail Information

Publications265 found, 100 shown here

  1. pmc Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage
    Kasirajan Ayyanathan
    Center for Molecular Biology and Biotechnology, Charles E Schmidt College of Science, Florida Atlantic University, Jupiter, Florida, United States of America
    PLoS ONE 7:e39949. 2012
    b>Sulindac is an FDA-approved non-steroidal anti-inflammatory drug with documented anticancer activities...
  2. pmc NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling
    Hu Zhou
    Institute for Biomedical Research, Xiamen University, Xiamen, Fujian 361005, China
    Cancer Cell 17:560-73. 2010
    ..Here, we report that Sulindac, an NSAID, induces apoptosis by binding to retinoid X receptor-alpha (RXRalpha)...
  3. pmc Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs
    X Li
    Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA
    Oncogene 31:4979-86. 2012
    ..Here, we show that the NSAID, sulindac sulfide (SS) can potently inhibit the invasion of human MDA-MB-231 breast and HCT116 colon tumor cells in vitro ..
  4. ncbi The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15
    Jong Sik Kim
    Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, MD E4 09, P O Box 12233, 111 TW Alexander Drive, Research Triangle Park, NC 27709, USA
    Mol Cancer Ther 4:487-93. 2005
    ..b>Sulindac sulfide was the most significant NSAID activated gene 1 (NAG-1) inducer and its expression was inversely ..
  5. pmc Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial
    Frank L Meyskens
    Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, California, USA
    Cancer Prev Res (Phila) 1:32-8. 2008
    ..gt; or =3 mm) adenomas were randomly assigned to receive oral difluoromethylornithine (DFMO) 500 mg and sulindac 150 mg once daily or matched placebos for 36 months, stratified by use of low-dose aspirin (81 mg) at baseline ..
  6. pmc Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer
    Ka Wing Cheng
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY, USA
    Int J Oncol 41:1199-203. 2012
    Phospho-sulindac (P-S, OXT-328), a novel sulindac derivative, has shown superior anticancer efficacy and safety compared to sulindac...
  7. ncbi Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis
    Frank G Bottone
    Laboratory of Molecular Carcinogenesis, the Laboratory of Computational Biology and Risk Analysis, and National Center for Toxicogenomics, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA
    J Biol Chem 278:25790-801. 2003
    ..One novel hypothesis is alterations in gene expression. To test this hypothesis sulindac sulfide, which is used to treat familial adenomatous polyposis, was selected to detect gene modulation in human ..
  8. ncbi The non-steroidal anti-inflammatory drugs Sulindac sulfide and Diclofenac induce apoptosis and differentiation in human acute myeloid leukemia cells through an AP-1 dependent pathway
    Raminder Singh
    Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
    Apoptosis 16:889-901. 2011
    ..CD34(+) selected de novo AML patient samples and the AML cell lines THP-1 and HL-60 were treated with the NSAIDs Sulindac sulfide and Diclofenac...
  9. ncbi Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons
    Amichand Dairam
    Faculty of Pharmacy, Rhodes University, P O Box 94, Grahamstown 6140, South Africa
    Metab Brain Dis 21:221-33. 2006
    ..antioxidant and neuroprotective properties of two non-steroidal anti-inflammatory drugs (NSAIDS), tolmetin and sulindac, using quinolinic acid (QA)-induced neurotoxicity as a model...
  10. ncbi High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors
    Anika Hansmann
    Department of General Surgery and Traumatology, Heinrich Heine University, Duesseldorf, Germany
    Cancer 100:612-20. 2004
    ..In the current study, high doses of tamoxifen in combination with sulindac were used to treat severe desmoid tumors to avoid surgery.
  11. ncbi Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells
    Y Huang
    Department of Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York 13210, USA
    Cancer Res 61:6918-24. 2001
    b>Sulindac is the most extensively investigated clinically relevant chemopreventive nonsteroidal anti-inflammatory drug...
  12. ncbi The metabolism of sulindac enhances its scavenging activity against reactive oxygen and nitrogen species
    Eduarda Fernandes
    REQUIMTE, Departamento de Quimica Fisica, Faculde de Farmácia da Universidade do Porto, Porto, Portugal
    Free Radic Biol Med 35:1008-17. 2003
    b>Sulindac is a sulfoxide prodrug that, in vivo, is converted to the metabolites sulindac sulfide and sulindac sulfone...
  13. pmc Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis
    Ulrike Stein
    Experimental and Clinical Research Center, Charite University Medicine, at the Max Delbrück Center for Molecular Medicine, Berlin, Germany
    Neoplasia 13:131-44. 2011
    ..Here we probe the hypothesis that the nonsteroidal anti-inflammatory drug sulindac sulfide can inhibit colon cancer metastasis by intervening in β-catenin signaling and thereby interdicting ..
  14. pmc Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
    H M Verheul
    Department of Surgery, Children s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Br J Cancer 79:114-8. 1999
    ..We found that sulindac was one of the most potent antiangiogenic NSAIDs, inhibiting bFGF-induced neovascularization by 50% and VEGF-..
  15. pmc Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity
    Chi C Wong
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, New York 11794 8173, USA
    J Pharmacol Exp Ther 340:422-32. 2012
    ..Kinetic analysis revealed that CES1 is more active in the hydrolysis of phospho-sulindac, phospho-ibuprofen, phospho-naproxen, phospho-indomethacin, and phospho-tyrosol-indomethacin that possessed a ..
  16. ncbi Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)
    M M Taketo
    Laboratory of Biomedical Genetics, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo, Japan
    J Natl Cancer Inst 90:1609-20. 1998
    ..This Part II (of a two-part review) focuses on the growing clinical and experimental evidence that NSAIDS and COX-2 inhibitors can influence the risk of colon (and possibly of other) cancers...
  17. ncbi Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer
    Naveen Babbar
    Arizona Cancer Center, and Biochemistry, Molecular and Cellular Biology Graduate Program, The University of Arizona, Tucson, 85724, USA
    J Biol Chem 278:47762-75. 2003
    b>Sulindac, a non-steroidal anti-inflammatory prodrug, is metabolized into pharmacologically active sulfide and sulfone derivatives...
  18. pmc Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles
    Rongrong Zhu
    Division of Cancer Prevention Department of Medicine, Stony Brook University, Stony Brook, New York, USA
    Pharm Res 29:3090-101. 2012
    To evaluate the antitumor efficacy of solid lipid nanoparticle-encapsulated phospho-sulindac (SLN-PS) in human lung cancer.
  19. pmc Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis
    Sandeep C Chaudhary
    Department of Dermatology, University of Alabama at Birmingham, 1530 3rd Avenue South, VH509, Birmingham, AL 35294 0019, USA
    Toxicol Appl Pharmacol 268:249-55. 2013
    ..Here, we show that NO-sulindac inhibited UVB-induced skin tumorigenesis in SKH-1 hairless mice...
  20. pmc The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats
    L Huang
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY, USA
    Br J Pharmacol 162:1521-33. 2011
    ..We evaluated the anti-inflammatory efficacy and safety of three novel modified NSAIDs, phospho-aspirin, phospho-ibuprofen and phospho-sulindac.
  21. ncbi FOXO3 is inhibited by oncogenic PI3K/Akt signaling but can be reactivated by the NSAID sulindac sulfide
    Carl Weidinger
    Clinic of Endocrinology, Department of Medicine, University Hospital Essen, Hufelandstr 55, D 45147 Essen, Germany
    J Clin Endocrinol Metab 96:E1361-71. 2011
    ..However, little is known about FOXO3 in the thyroid context...
  22. pmc Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts
    Caihua Zhu
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, New York 11794 8173, USA
    Stem Cells 30:2065-75. 2012
    ..These results indicate that PS has a strong inhibitory effect against breast cancer, acting, at least in part, by targeting CSCs through a signaling mechanism involving Wnt signaling...
  23. ncbi Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines
    M A Rahman
    Second Department of Surgery, Shimane Medical University, Izumo, Japan
    Cancer Res 60:2085-9. 2000
    This is the first report enumerating a superb antiproliferative effect of both sulindac and exisulind on hepatocellular cancer cell lines...
  24. ncbi The effect of long-term treatment with sulindac on the progression of diabetic retinopathy
    Yukiko Hattori
    Department of Internal Medicine, Asama General Hospital, Saku, Japan
    Curr Med Res Opin 23:1913-7. 2007
    To evaluate the effects of long-term treatment with sulindac on the progression of diabetic retinopathy (DR).
  25. pmc Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice
    Gerardo G MacKenzie
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, New York 11794 8173, USA
    Gastroenterology 139:1320-32. 2010
    ..However, chronic administration of NSAIDs is associated with significant side effects, mainly of the gastrointestinal tract. Given these limitations, we synthesized phospho-sulindac (P-S; OXT-328), a novel sulindac derivative.
  26. ncbi The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB
    C J Loveridge
    Colon Cancer Genetics Group, University of Edinburgh Cancer Research Centre, School of Clinical and Molecular Medicine and MRC Human Genetics Unit, Western General Hospital, Edinburgh, Scotland, UK
    Oncogene 27:2648-55. 2008
    ..Here, we demonstrate that sulindac, sulindac sulfone and indomethacin activate the NF-kappaB pathway in colorectal cancer cells, as determined by ..
  27. pmc The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine
    G Xie
    Department of Medicine, Stony Brook University, Stony Brook, NY, USA
    Br J Pharmacol 165:2152-66. 2012
    Phospho-sulindac (PS; OXT-328) prevents colon cancer in mice, especially when combined with difluoromethylornithine (DFMO). Here, we explored its metabolism and pharmacokinetics.
  28. pmc A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity
    Gary A Piazza
    Drug Discovery and Development Divisions, Southern Research Institute, Birmingham, Alabama 35205, USA
    Cancer Prev Res (Phila) 2:572-80. 2009
    Nonsteroidal anti-inflammatory drugs such as sulindac have shown promising antineoplastic activity, although toxicity from cyclooxygenase (COX) inhibition and the suppression of prostaglandin synthesis limits their use for chemoprevention...
  29. ncbi Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Room 041, Building R4, 1044 West Walnut Street, Indianapolis, IN 46202, USA
    Mol Cancer Ther 4:587-94. 2005
    ..cells to NSAID inhibition, BxPC-3, PANC-1, and MIA PaCa-2 cells were treated with parthenolide and the NSAID sulindac, either alone or in combination...
  30. pmc Sulindac enhances the killing of cancer cells exposed to oxidative stress
    Maria Marchetti
    Center for Molecular Biology and Biotechnology, Florida Atlantic University, Boca Raton, Florida, United States of America
    PLoS ONE 4:e5804. 2009
    b>Sulindac is an FDA-approved non-steroidal anti-inflammatory drug (NSAID) that affects prostaglandin production by inhibiting cyclooxygenases (COX) 1 and 2...
  31. ncbi MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Pancreas 27:337-44. 2003
    ..In addition, we investigated whether the MEK-ERK pathway influenced the response of pancreatic cancer cells to nonsteroidal antiinflammatory drugs (NSAIDs)...
  32. pmc Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice
    Gerardo G MacKenzie
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
    Cancer Prev Res (Phila) 4:1052-60. 2011
    The nonsteroidal anti-inflammatory drug (NSAID) sulindac and the ornithine decarboxylase (ODC) antagonist difluoromethylornithine (DFMO), individually and together, are effective inhibitors of colon carcinogenesis...
  33. ncbi A sulindac analogue is effective against malignant pleural effusion in mice
    Charalampos Moschos
    Applied Biomedical Research and Training Center Marianthi Simou and George P Livanos Laboratory, Athens, Greece
    Lung Cancer 73:171-5. 2011
    To examine whether a sulindac derivative (C-18) with previously reported anti-angiogenic properties limits malignant pleural effusion (MPE) formation in mice.
  34. ncbi The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis
    N N Mahmoud
    The New York Hospital Cornell University Medical Center, NY 10021, USA
    Carcinogenesis 19:87-91. 1998
    b>Sulindac, a non-steroidal anti-inflammatory drug (NSAID), is effective in treating intestinal adenomas in humans with Familial Adenomatous Polyposis (FAP) and in preventing intestinal tumors in the C57Bl/6J-Min+ (Min) mouse, an animal ..
  35. pmc The cyclooxygenase inhibitor sulindac sulfide inhibits EP4 expression and suppresses the growth of glioblastoma cells
    Atsushi Kambe
    Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC 27709, USA
    Cancer Prev Res (Phila) 2:1088-99. 2009
    EP4 expression in human glioblastoma cells correlates with growth on soft agar. The cyclooxygenase inhibitor sulindac sulfide first altered specificity protein-1 (Sp-1) and early growth response gene-1 expression, then increased the ..
  36. ncbi Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Pancreas 42:160-7. 2013
    ..dimethylaminoparthenolide (DMAPT), a bioavailable nuclear factor-κB inhibitor, and the cyclooxygenase inhibitors sulindac and celecoxib have potential chemotherapeutic efficacy...
  37. ncbi A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer
    R O'CONNOR
    The National Institute for Cellular Biotechnology, Dublin City University, Dublin, 9, Ireland
    Cancer Chemother Pharmacol 59:79-87. 2007
    ..b>Sulindac has been shown to be a competitive substrate for the clinically important resistance protein, multi-drug ..
  38. ncbi Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity
    Takae Minami
    First Department of Internal Medicine, Graduate School of Medicine, Sapporo Medical University, Sapporo, Japan
    Clin Cancer Res 11:5248-56. 2005
    The nonsteroidal antiinflammatory drug sulindac is a promising chemopreventive agent against colon cancer...
  39. ncbi A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation
    Hyeon Ok Jin
    Laboratory of Radiation Resistance Control, Korea Institute of Radiological and Medical Sciences, Nowon Gu, Seoul, Republic of Korea
    Lung Cancer 61:317-27. 2008
    In the present study, we show that a combination of sulindac and arsenic trioxide (ATO) induces more extensive apoptosis than either drug alone in H1299 human non-small cell lung carcinoma (NSCLC) cells...
  40. ncbi Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps
    Tetsuji Takayama
    Department of Gastroenterology and Oncology, Institutes of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan
    Clin Cancer Res 17:3803-11. 2011
    ..preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention of ..
  41. ncbi Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells
    Theresia Karl
    Deutsches Krebsforschungszentrum, Forschungsschwerpunkt Angewandte Tumorvirologie, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
    Cancer Lett 245:103-11. 2007
    b>Sulindac, a nonsteroidal anti-inflammatory drug (NSAID), induces growth arrest in HeLa cells and causes strong inhibition of the G1 to S transition of the cell cycle in a concentration-dependent manner...
  42. pmc Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients
    Jason A Zell
    Chao Family Comprehensive Cancer Center, Department of Epidemiology, University of California Irvine, 224 Irvine Hall, Irvine, CA 92697, USA
    J Natl Cancer Inst 102:1513-6. 2010
    ..We investigated the effects of ODC1 after treatment with difluoromethylornithine (eflornithine)/sulindac or placebo...
  43. pmc Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma
    Patricia A Thompson
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724 5024, USA
    Gastroenterology 139:797-805, 805.e1. 2010
    ..We studied effects of the combination of difluoromethylornithine (DFMO) and sulindac on biomarkers and investigated factors that modify their efficacy.
  44. ncbi Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells
    Pamela L Rice
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Mol Cancer Ther 2:885-92. 2003
    ..Substantial clinical, epidemiological, and animal evidence indicate that sulindac and other non-steroidal anti-inflammatory drugs (NSAIDs) prevent the development of CRC...
  45. ncbi Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
    M Oshima
    Banyu Tsukuba Research Institute Merck, Okubo, Japan
    Cell 87:803-9. 1996
    ..treating Apc delta716 mice with a novel COX-2 inhibitor reduced the polyp number more significantly than with sulindac, which inhibits both isoenzymes...
  46. ncbi Nonsteroidal anti-inflammatory drugs and oxidative stress in cancer cells
    M Adachi
    First Department of Internal Medicine, Graduate School of Medicine, Sapporo Medical University, Sapporo, Japan
    Histol Histopathol 22:437-42. 2007
    ..In addition, the classical NSAIDs sulindac and aspirin are promising chemopreventive agents against colon cancer...
  47. ncbi Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study
    Marcia Cruz-Correa
    Department of Medicine, Division of Gastroenterology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Gastroenterology 122:641-5. 2002
    ..b>Sulindac, a nonsteroidal anti-inflammatory drug, causes regression of colorectal adenomas in the retained rectal segment ..
  48. pmc Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas
    Jason A Zell
    Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA
    Cancer Prev Res (Phila) 2:209-12. 2009
    ..of baseline CV risk on adverse CV events in a phase III trial of difluoromethylornithine (DFMO) plus the NSAID sulindac versus placebo in preventing colorectal adenomas. Trial data were analyzed to determine baseline CV risk...
  49. ncbi Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats
    Michael H Mesches
    Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA
    Neurobiol Aging 25:315-24. 2004
    ..b>Sulindac, an NSAID that is a nonselective cyclooxygenase (COX) inhibitor was chronically administered to aged Fischer 344 ..
  50. ncbi Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells
    L J Hixson
    Department of Medicine, University of Arizona, Tucson 85724
    Cancer Epidemiol Biomarkers Prev 3:433-8. 1994
    ..These include animal experiments, case-control studies, and clinical experience with sulindac in promoting the regression of adenomatous colon polyps in adenomatous polyposis coli...
  51. pmc Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds
    Liqun Huang
    Department of Medicine, Division of Cancer Prevention, Stony Brook University, Stony Brook, New York 11794, USA
    Cancer Res 71:7617-27. 2011
    ..In vivo investigations confirmed the antitumor activity of phospho-aspirin (PA) and phospho-sulindac (PS) in inhibiting tumor growth in established human xenograft models, in which cell proliferation was suppressed ..
  52. pmc Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect
    Liqun Huang
    Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY 11794, USA
    Carcinogenesis 31:1982-90. 2010
    Non-steroidal anti-inflammatory drugs such as sulindac are promising chemoprevention agents against colon cancer, but their weak potency and side effects limit their use for both chemoprevention and chemotherapy...
  53. pmc Sulindac suppresses beta-catenin expression in human cancer cells
    Anjia Han
    Department of Pathology, University of Illinois at Chicago, Chicago, IL 60612, USA
    Eur J Pharmacol 583:26-31. 2008
    b>Sulindac has been reported to be effective in suppressing tumor growth through the induction of p21WAF1/cip1 in human, animal models of colon cancer and colon cancer cells...
  54. ncbi Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation
    Nancy L Cho
    Department of Surgery, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Thyroid 20:615-22. 2010
    ..In this study, we tested the hypothesis that the nonsteroidal antiinflammatory drug sulindac would reverse aberrant beta-catenin activity in thyroid cancer cells.
  55. ncbi Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta
    A Mi Seo
    Research Center for Women s Diseases, Division of Biological Sciences, Sookmyung Women s University, Seoul 140 742, Korea
    Apoptosis 14:913-22. 2009
    b>Sulindac is a non-steroidal anti-inflammatory agent with anti-tumor activities that include the induction of apoptosis in various cancer cells and the inhibition malignant transformation...
  56. ncbi Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane
    Tomokazu Ohishi
    School of Food and Nutritional Sciences, University of Shizuoka, 52 1 Yada, Shizuoka 422 8526, Japan
    Cancer Lett 177:49-56. 2002
    ..b>Sulindac is also well known as a cancer-preventive agent against colon cancer, but its usage is restricted because of its ..
  57. pmc Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice
    Hector Guillen-Ahlers
    W M Keck Center for Transgene Research, University of Notre Dame, Notre Dame, IN 46556, USA
    Carcinogenesis 29:1421-7. 2008
    ..In this study, Apc(Min/+) mice, a genetic model of human familial adenomatous polyposis, were treated with sulindac, and these mice demonstrated tumor reduction of >80%, consistent with previous reports...
  58. ncbi Effects of sulindac, sulindac metabolites, and aspirin on the activity of detoxification enzymes in HT-29 human colon adenocarcinoma cells
    E J Patten
    Department of Environmental and Occupational Health, School of Public Health, Emory University, Atlanta, GA 30322, USA
    Cancer Lett 147:95-100. 1999
    ..In this study we examined the effect of sulindac, sulindac sulfide, sulindac sulfone and aspirin on QR and GST activity...
  59. pmc Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice
    Chung Wei Lee
    Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Cancer Res 69:8166-74. 2009
    ..We examined the efficacy of the nonsteroidal anti-inflammatory drug sulindac (400 ppm in drinking water) alone, the CCK2/gastrin receptor antagonist YM022 (45 mg/kg/wk) alone, and sulindac ..
  60. ncbi Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice
    Hiroshi Yasui
    First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
    Cancer 97:1412-20. 2003
    ..Recently, a nonsteroidal antiinflammatory drug, sulindac, and its metabolites have been shown to inhibit the NF-kappaB pathway and to enhance TNF-alpha-mediated apoptosis ..
  61. ncbi Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide
    Sylwia Flis
    National Medicine Institute, Department of Pharmacology, Warsaw, Poland
    Anticancer Res 29:435-41. 2009
    ..aim of this study was to compare growth inhibitory effects of cytostatics (5-fluorouracil, 5-FU; oxaliplatin) and COX inhibitor sulindac sulfide (an active metabolite of sulindac), given alone or in combination, on several CRC cell lines.
  62. pmc Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase
    Dhananjay P Kunte
    Feinberg School of Medicine at Northwestern University, Department of Internal Medicine, Evanston Northwestern Healthcare, 2650 Ridge Avenue, Suite G208, Evanston, IL 60201, USA
    Mol Cancer Ther 7:1797-806. 2008
    ..In the azoxymethane-treated rat model of experimental colon carcinogenesis, sulindac treatment markedly induced Csk with a corresponding increase in inhibitory phosphorylation of Src (Tyr(527))...
  63. pmc JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo
    Zibo Song
    Department of Oncology, Albert Einstein Cancer Center, Bronx, NY 10467, USA
    Eur J Pharmacol 560:95-100. 2007
    Our previous studies demonstrated that sulindac, a non-steroidal anti-inflammatory drug, suppressed intestinal tumor formation in mouse, which is linked to the induction of wild-type p53-activated fragment 1 (p21WAF1, or p21)...
  64. ncbi Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone
    Piotr Skopinski
    Second Department of Ophtalmology, Medical University of Warsaw, 13 Sierakowskiego street, 03 709 Warsaw, Poland
    Int J Mol Med 14:707-11. 2004
    ..The aim of the present study was to compare the anti-angiogenic effectiveness of sulindac sulfone and some herbal compounds in the serum-induced angiogenesis test performed in Balb/c mice...
  65. ncbi Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo
    Michele T Yip-Schneider
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Mol Cancer Ther 6:1736-44. 2007
    ..with NF-kappaB inhibition, enhanced the growth suppression of pancreatic cancer cells by the COX inhibitor sulindac in vitro...
  66. pmc Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells
    Heather N Tinsley
    Drug Discovery Division, Southern Research Institute, Birmingham, Alabama, USA
    Cancer Prev Res (Phila) 4:1275-84. 2011
    Nonsteroidal anti-inflammatory drugs (NSAID) such as sulindac sulfide (SS) display promising antineoplastic properties, but toxicities resulting from COX inhibition limit their clinical use...
  67. pmc Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations
    Osamu Itano
    Strang Cancer Research Laboratory, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Carcinogenesis 30:1923-6. 2009
    We have previously reported that sulindac, a non-steroidal anti-inflammatory drug, inhibited tumor formation in the small intestine but increased tumors in the colon of Apc(Min/+) mice, a model of human familial adenomatous polyposis...
  68. ncbi Sulindac sulfide and caffeic acid phenethyl ester suppress the motility of lung adenocarcinoma cells promoted by transforming growth factor-beta through Akt inhibition
    Yasushi Shigeoka
    Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University, 86 Nishimachi, 683 8503 Yonago, Japan
    J Cancer Res Clin Oncol 130:146-52. 2004
    ..Potential chemopreventive agents of cancer-sulindac sulfide, caffeic acid phenethyl ester (CAPE), curcumin, and (+)-catechin-have been reported to interfere with ..
  69. ncbi Suppression of growth arrest and DNA damage-inducible 45alpha expression confers resistance to sulindac and indomethacin-induced gastric mucosal injury
    Shiun Kwei Chiou
    Department of Veterans Affairs Medical Center, 5901 E 7th St, Long Beach, CA 90822 5201, USA
    J Pharmacol Exp Ther 334:693-702. 2010
    Nonsteroidal anti-inflammatory drugs (NSAIDs) such as sulindac and indomethacin are a major cause of gastric erosions and ulcers. Induction of apoptosis by NSAIDs is an important mechanism involved...
  70. pmc Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G
    Heather N Tinsley
    Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL 35205, USA
    Mol Cancer Ther 8:3331-40. 2009
    b>Sulindac displays promising antineoplastic activity, but toxicities from cyclooxygenase inhibition limit its use for chemoprevention...
  71. pmc Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition
    Heather N Tinsley
    Department of Pharmacology and Toxicology, University of Alabama at Birmingham, USA
    Cancer Prev Res (Phila) 3:1303-13. 2010
    ..Here, we show that the NSAID sulindac sulfide (SS) inhibits cyclic guanosine 3',5'-monophosphate (cGMP) phosphodiesterase (PDE) activity in colon tumor ..
  72. ncbi Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells
    Henry P Ciolino
    Division of Nutritional Sciences, Department of Human Ecology, University of Texas at Austin, Austin, TX, USA
    Int J Cancer 122:990-8. 2008
    b>Sulindac is a nonsteroidal antiinflammatory drug that has been demonstrated to be a potent chemopreventive agent against colorectal cancer in both human and animal models...
  73. ncbi Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after Sulindac therapy
    R Masunaga
    Second Department of Surgery, Shimane Medical University, Izumo 693-8501, Japan
    Dis Colon Rectum 44:1008-15. 2001
    PURPOSE: We tried to elucidate the effects of sulindac on human colorectal carcinoma. METHODS: Sulindac (300 mg/day) was administered for two weeks before operation to 33 patients with sporadic colorectal carcinoma (Sulindac Group)...
  74. ncbi Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta)
    Dae J Kim
    Department of Veterinary and Biomedical Sciences and The Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA, 16802, USA
    Carcinogenesis 27:1105-12. 2006
    ..32 g sulindac/kg diet...
  75. ncbi Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer
    Teresa A Zimmers
    Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
    J Cancer Res Clin Oncol 136:571-6. 2010
    ..We sought to determine the effect of loss of Gdf15 on animal tumor models of hereditary colon cancer and in the NSAID-mediated prevention of heritable colorectal cancer...
  76. pmc Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold
    Andy J Liedtke
    A B Hancock Jr Memorial Laboratory for Cancer Research, Department of Biochemistry, Vanderbilt Institute of Chemical Biology, Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    J Med Chem 55:2287-300. 2012
    ..We designed, synthesized, and evaluated a series of (E)-2'-des-methyl-sulindac sulfide (E-DMSS) analogues for inhibition of COX-1...
  77. pmc A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy
    Evrim Gurpinar
    Department of Pharmacology and Toxicology, The University of Alabama at Birmingham, Birmingham, Alabama, USA
    Mol Cancer Ther 12:663-74. 2013
    Nonsteroidal anti-inflammatory drugs such as sulindac sulfide have shown promising antineoplastic activity in multiple tumor types, but toxicities resulting from COX inhibition limit their use in cancer therapy...
  78. pmc Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice
    Emily J Greenspan
    Center for Molecular Medicine, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 3101, USA
    Cancer Prev Res (Phila) 3:1187-97. 2010
    Although nonsteroidal anti-inflammatory drugs (NSAID), including sulindac, have been used extensively as chemopreventive agents for colorectal cancer, results are not consistent...
  79. ncbi Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells
    Y L Wu
    Department of Gastroenterology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China
    World J Gastroenterol 7:796-800. 2001
    To evaluate the effects of sulindac in inducing growth inhibition and apoptosis of human gastric cancer cells in comparison with human hepatocellular carcinoma (HCC) cells.
  80. pmc Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention
    Paul J Limburg
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Cancer Prev Res (Phila) 4:259-69. 2011
    b>Sulindac, atorvastatin, or prebiotic dietary fiber may reduce colorectal cancer (CRC) risk. However, clinical trial data are currently limited...
  81. ncbi A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104
    Ramaswamy Govindan
    Washington University School of Medicine and Alvin J Siteman Cancer Center, St Louis, MO 63110, USA
    J Thorac Oncol 4:220-6. 2009
    ..To assess the efficacy and toxicity of carboplatin, etoposide, and exisulind as initial therapy for extensive stage small cell lung cancer...
  82. ncbi Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses
    Lionel Resnick
    Center for Molecular Biology and Biotechnology, Florida Atlantic University, Boca Raton, FL 33431, USA
    J Drugs Dermatol 8:29-32. 2009
    ..b>Sulindac is a Food and Drug Administration (FDA)-approved nonsteroidal anti-inflammatory drug (NSAID) that has been shown ..
  83. pmc p27kip1 in intestinal tumorigenesis and chemoprevention in the mouse
    Wancai Yang
    Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY, USA
    Cancer Res 65:9363-8. 2005
    ..of another cyclin-dependent kinase inhibitor, p21(WAF1/cip1), the nonsteroidal anti-inflammatory drug sulindac was still effective in inhibiting intestinal tumor formation in Apc(+/-),p27(+/-) or Apc(+/-),p27(-/-) mice, ..
  84. ncbi Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells
    M C Jiang
    Institute of Zoology, Academia Sinica, Taipei, 115, Taiwan
    Biochem Biophys Res Commun 282:671-7. 2001
    ..Aspirin is a cyclooxygenase (COX) inhibitor. Treatment of cells with another COX inhibitor, sulindac, also inhibited MMP-2 activity and increased E-cadherin production of cells...
  85. ncbi The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells
    Tao Zhang
    Division of Genetic and Preventive Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    J Pharmacol Exp Ther 308:434-7. 2004
    Nonsteroidal anti-inflammatory drugs (NSAIDs) such as sulindac have chemopreventive activity against colorectal tumors...
  86. ncbi A case of Cronkhite-Canada syndrome with colorectal adenomas: effect of the nonsteroidal anti-inflammatory drug sulindac
    Kazuoki Hizawa
    Am J Gastroenterol 102:1831-2. 2007
  87. ncbi New TNF-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen
    Hirota Fujiki
    Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro cho, Tokushima 770 8514, Japan
    Mutat Res 523:119-25. 2003
    ..green tea as a cancer preventive, we review two important results with EGCG: the synergistic effects of EGCG with sulindac or tamoxifen on cancer preventive activity in PC-9 cells, and cancer prevention of intestinal tumor development ..
  88. ncbi Synthesis, pharmacological evaluation and docking studies of new sulindac analogues
    Nelilma C Romeiro
    Laboratório de Avaliação e Síntese de Substâncias Bioativas LASSBio, Faculdade de Farmacia, Universidade Federal do Rio de Janeiro UFRJ, Rio de Janeiro, PO Box 68023, RJ 21944 970, Brazil
    Eur J Med Chem 44:1959-71. 2009
    This paper describes the synthesis, pharmacological evaluation and docking studies of a series of new sulindac analogues...
  89. ncbi Synergistic action of doxorubicin and sulindac in human cervix carcinoma cells - studies on possible mechanisms
    Beata Maria Gruber
    Department of Biochemistry and Biopharmaceuticals, National Medicines Institute, Warsaw, Poland
    Med Sci Monit 16:BR45-51. 2010
    ..The aim of the current work was to study the mechanisms of synergistic action noted in HeLa cervical carcinoma cells under doxorubicin (DOX) and sulindac (SUL) co-treatment.
  90. ncbi Methylation in the p21WAF1/cip1 promoter of Apc+/-, p21+/- mice and lack of response to sulindac
    Wancai Yang
    Department of Oncology, Montefiore Medical Center, Albert Einstein Cancer Center, 111 East 210th Street, Bronx, NY 10467, USA
    Oncogene 24:2104-9. 2005
    ..and that inactivation of only one p21 allele was also sufficient to abrogate duodenal tumor inhibition by sulindac, a nonsteroidal anti-inflammatory drug...
  91. ncbi Differential activity of sulindac metabolites against squamous cell carcinoma of the head and neck is mediated by p21waf1/cip1 induction and cell cycle inhibition
    Jonathan M Bock
    Department of Otoloryngology, Head and Neck Surgery, University of Iowa Health Care, Iowa City, Iowa 52242, USA
    Cancer Biol Ther 6:30-9. 2007
    b>Sulindac sulfide and sulindac sulfone have demonstrated anti-neoplastic and chemo-preventive activity against various human tumors, but few studies have examined the relative effectiveness of these drugs against squamous cell carcinoma of ..
  92. ncbi Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2
    Hyung Chahn Lee
    Laboratory of Cell Biology, Department of Laboratory Medicine and Clinical Pathology, Korea Cancer Center Hospital, Seoul 139 240, Korea
    J Cell Biochem 94:597-610. 2005
    Non-steroidal anti-inflammatory drug (NSAID), sulindac has chemopreventive and anti-tumorigenic properties, however, the molecular mechanism of this inhibitory action has not been clearly defined...
  93. pmc Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα
    Gunnar Steinert
    Department of Hematology, Goethe University, Frankfurt, Germany
    PLoS ONE 6:e22540. 2011
    ..To better investigate whether NSAID treatment is effective, we used Sulindac Sulfide in X-RARα-positive progenitor cell models...
  94. ncbi Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor
    G Lal
    Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Department of Surgery, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, M5G 1X5 Canada
    Cancer Res 61:6131-6. 2001
    ..to inhibit intestinal polyps in Apc(Delta716) mice more effectively than dual COX-1/COX-2 inhibitors such as sulindac. Various Apc knockout mice, including the multiple intestinal neoplasia (Min) mouse and the Apc(Delta716) mouse, ..
  95. ncbi PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells
    Nikolaos G Nikitakis
    Department of Diagnostic Sciences and Pathology, University of Maryland, Baltimore, MD 21201 1586, USA
    Int J Cancer 98:817-23. 2002
    There is strong evidence that nonsteroidal antiinflammatory drug (NSAID) sulindac may exert a significant antineoplastic effect...
  96. ncbi [Antitumor effects of sulindac in ovarian cell cultures]
    Anna Jakubowska-Mućka
    Zakład Immunologii, Centrum Onkologii Instytut im Marii Sklodowskiej Curie, Warszawa, Polska
    Ginekol Pol 82:195-9. 2011
    ..The purpose of our study was to assess susceptibility of cells of various ovarian cell lines on different nonsteroidal anti-inflammatory drugs (NSAIDs)...
  97. ncbi Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis
    Takayuki Matsumoto
    Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    J Gastroenterol Hepatol 21:251-7. 2006
    The aim of the present study was to elucidate the effect of sulindac on uncolectomized familial adenomatous polyposis (FAP).
  98. pmc Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity
    Clara Curiel-Lewandrowski
    College of Medicine, Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724 5024, USA
    Cancer 118:5848-56. 2012
    ..However, the ability of NSAIDs to reach melanocytes in vivo and modulate key biomarkers in preneoplastic lesions such as atypical nevi has not been evaluated...
  99. ncbi Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac
    Li Ma
    Department of Gastroenterology, Second Affiliated Hospital, Lanzhou Medical University, Lanzhou 730000, Gansu Province, China
    World J Gastroenterol 11:1829-32. 2005
    To investigate the effects of mitomycin (MMC) combined with sulindac on cell viability, apoptotic induction and expression of apoptosis-related gene Bcl-2 and cyclooxygenase-2 (COX-2) in gastric cancer SGC-7901 cells.
  100. ncbi Antiproliferative effects of S-allylmercaptocysteine on colon cancer cells when tested alone or in combination with sulindac sulfide
    H Shirin
    Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Cancer Res 61:725-31. 2001
    ..For comparison, we included the compound sulindac sulfide (SS), because sulindac compounds are well-established colon cancer chemopreventive agents...
  101. ncbi Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer?
    F Tonelli
    Department of Clinical Physiopathology, Surgical Unit, University of Florence, Italy
    J Surg Oncol 74:15-20. 2000
    Ileorectal anastomosis (IRA) is still used in the treatment of familial adenomatous polyposis (FAP). Sulindac appears to induce regression of colorectal adenomas; however, its effects in long-term therapy and in preventing carcinoma ..

Research Grants62

  1. Combined Chemoprevention in Beta-Catenin Mutant Mice
    Gayle Orner; Fiscal Year: 2004
    ..A combination of tea plus the NSAID sulindac was recently shown to be highly effective at preventing the formation of tumors in Apc[min] mice...
  2. Nanotheranostics for Early Colorectal Cancer Detection and Treatment
    Jeffrey S Souris; Fiscal Year: 2013
    ..will characterize the utility of fluorescent MSNs whose interiors are tiled with pH-triggered releasable NSAIDs (sulindac sulfide, celecoxib, or acetylsalicylic acid) and whose exteriors are covered with lectins/aptamers/peptides that ..
  3. Dual Modality System for Imaging Colon Cancer in Mice
    Jennifer Kehlet Barton; Fiscal Year: 2013
    ..to adenoma and/or adenocarcinoma? b) Can treatment with [unreadable]-difluoromethylornithine (DFMO) and/or sulindac regress adenoma and prevent adenocarcinoma? c) What role does the RAS oncogene play in sulindac prevention of ..
  4. Discovery Tools for Chemotherapy Resistance to Cell Death.
    Robert W Sobol; Fiscal Year: 2012
    ..endpoints and selective response to apoptosis inducing agents (Temozolomide, Camptothecin, staurosporine and Sulindac)...
  5. Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis
    Guang Yu Yang; Fiscal Year: 2013
    ..3) Diclofenac and Sulindac [non- steroidal anti-inflammatory drugs (NSAIDs)] are competitive inhibitors of AKR1B10...
  6. A novel mouse colon cancer model and chemoprevention
    Wei Dai; Fiscal Year: 2010
    ..Moreover, chemopreventive compounds such as sulindac sulfide and S-allylmercaptocysteine are capable of inducing apoptosis in HT-29 and SW-480 colon tumor cells;BubRl ..
  7. Chemopreventive Effect of NSAIDs Against Prostate Cancer
    Bhagavathi Narayanan; Fiscal Year: 2009
    ..It is not clear however, whether selective COX-2 inhibitors, or exisulind, a metabolic product of sulindac (NSAID), exert their potentially beneficial effects either by blocking COX-2 or by stimulating programmed cell ..
  8. Phosphosulindac, miRNAs and cancer racial disparity
    Jennie L Williams; Fiscal Year: 2013
    ..A promising colon cancer chemopreventive agent, phospho-sulindac (P-S), inhibits colon cancer cell growth more potently than sulindac by inhibiting cell proliferation and ..
  9. PDEF and survivin: cancer prognosis, initiation, progression and metastasis
    Fengzhi Li; Fiscal Year: 2010
    ..Accordingly, many natural dietary components, including resveratrol, silibinin, sulindac, retinoid, selenium and vitamin D compounds that have cancer-preventive and therapeutic effects, downregulate ..
  10. Nsaid Effects on Clinical and Imaging Breast Biomarkers
    PATRICIA ANN THOMPSON; Fiscal Year: 2013
    ..A need to maximize AI efficacy is evident. Non-steroidal anti-inflammatory agents (NSAIDs), particularly sulindac, demonstrate potent and mechanistically supported anti-cancer activity for breast tumors in preclinical models...
  11. Aspirin-PC for Chemoprevention of Colorectal Cancer
    Lenard M Lichtenberger; Fiscal Year: 2013
    ..coated (EC)- aspirin (the over-the-counter/OTC aspirin most commonly available and consumed by the public), and sulindac (an NSAID with known chemopreventive efficacy) are orally administered (in Torpac minicapsules) at a range of ..
  12. Using Mouse Endoscopy for Evaluating Colon Cancer
    DANIEL WILLIAM ROSENBERG; Fiscal Year: 2012
    ..We will use sulindac, currently being tested in an NCI multi-center pilot chemoprevention clinical trial (CPN), as a model ..
  13. Colon Cancer Prevention with Phospho-Sulindac
    Basil Rigas; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): A significant development in combination chemoprevention is the use of sulindac plus difluoromethylornithine (DFMO), which was recently demonstrated to reduce the recurrence of all human colon ..
  14. Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer Chemopreventi
    Gary A Piazza; Fiscal Year: 2013
    ..We have found that the tumor cell growth inhibitory and apoptosis inducing properties of certain NSAIDs such as sulindac sulfide (SS) are closely associated with inhibition of the cGMP-specific phosphodiesterase, PDE5...
  15. MicroRNA, sulindac, and breast cancer chemoprevention
    Yaguang Xi; Fiscal Year: 2013
    ..us to hypothesize that specific microRNAs (miRNAs) can mediate the cancer chemopreventive activity of the NSAID sulindac sulfide (SS)...
  16. SMAC in chemoprevention of colon cancer
    Lin Zhang; Fiscal Year: 2011
    ..Furthermore, activation of SMAC and agents that mimic the function of SMAC can enhance the apoptotic response to sulindac, an NSAID commonly used in chemoprevention...
  17. Development of a novel sulindac amide for colorectal cancer chemoprevention
    Gary A Piazza; Fiscal Year: 2013
    ..To develop this approach, we used molecular modeling to identify specific chemical properties of the NSAID, sulindac sulfide (SS) that are crucial for COX-1 and COX-2 binding...
  18. Role of tRXRalpha in pancreatic cancer development and therapy
    Xiao Kun Zhang; Fiscal Year: 2013
    ..with PI3K in the cytoplasm to mediate the TNF? signaling and that the nonsteroidal anti-inflammatory drug (NSAID) Sulindac could bind to tRXR? to regulate tRXR?-mediated TNF? signaling pathways (Cancer Cell 17, 560, 2010)...
  19. Novel Sulindac Derivatives for Colon Cancer Chemoprevention
    Robert C Reynolds; Fiscal Year: 2013
    ..Preliminary studies suggest that the mechanism for the chemopreventive activity of a highly efficacious NSAID, sulindac, does not require the inhibition of COX-1 or -2 and that cyclic guanosine monophosphate phosphodiesterase (cGMP ..
  20. Polyphenon E for the Chemoprevention of Colorectal Cancer
    Frank A Sinicrope; Fiscal Year: 2013
    ..Importantly, short-term administration of the nonselective COX inhibitor sulindac was shown to regress rectal ACF in high risk patients in a small, open- label trial from Japan...
  21. NSAID and COX/PG Metabolism and Colorectal Cancer
    Cornelia Ulrich; Fiscal Year: 2009
    ..in vitro studies, which of the UGTs catalyze the glucuronidation of aspirin and other NSAIDs including ibuprofen, sulindac, sulindac sulfone, and indomethacin, and the effects of polymorphisms on metabolic capacities...
  22. An agent for the treatment of lung cancer
    Despina Komninou; Fiscal Year: 2012
    ..Our preliminary data indicate that the novel compound phospho-sulindac (PS) is potentially highly effective against lung cancer...
  23. Altered Arachidonic Acid Balance and Colon Cancer
    DANIEL WILLIAM ROSENBERG; Fiscal Year: 2010
    ..Aim 3 will test the influence of cPLA2 on chemoprevention by the Cox inhibitor, sulindac. Efficacy will be evaluated in mice with normal or reduced levels of cPLA2...
  24. The Role of Aryl Hydrocarbon Receptor in Colon Tumorigenesis
    GREGORY DEAN KENNEDY; Fiscal Year: 2013
    ..occurring dietary compounds such as indole-3- carbinol, chrysin and curcumin, as well as therapeutic agents like Sulindac and other NSAIDs...
  25. Bid-mediated killing of oncogenic stem cells in chemoprevention
    Lin Zhang; Fiscal Year: 2013
    ..Deficiency in Bid almost completely abolished the chemopreventive effect of the NSAID sulindac in APC/Min mice, a commonly used chemoprevention model...
  26. MDC-1231 for cancer prevention
    Basil Rigas; Fiscal Year: 2010
    ..A significant development in the prevention of colon cancer is the combined use of sulindac and difluoromethylornithine (DFMO);sulindac stimulates polyamine acetylation and export from the cell and DFMO ..
  27. The role of the aryl hydrocarbon receptor in colon tumorigenesis
    GREGORY DEAN KENNEDY; Fiscal Year: 2012
    ..occurring dietary compounds such as indole-3- carbinol, chrysin and curcumin, as well as therapeutic agents like Sulindac and Omeprazole...
  28. Combined effects of tea plus NSAIDS towards colon cancer
    Gayle Orner; Fiscal Year: 2004
    ..Our preliminary data shows that tea or a combination of tea plus the NSAID sulindac is highly effective at preventing the formation of tumors in Apc m/In mice...
  29. MDC-1231 for cancer prevention
    Basil Rigas; Fiscal Year: 2013
    ..It was recently shown that the combination of sulindac with difluoromethylornithine (DFMO) prevents nearly 70% of colon cancer, assessed as colon polyp recurrence...
  30. Serum Biomarkers of Hepatic Response to Cancer Chemopreventive Intervention
    John Groopman; Fiscal Year: 2009
    ..Chemopreventive agents (e.g. sulforaphane, sulindac) originally thought to primarily work by altering classically described phase I and II metabolism or directly ..
  31. Prevention of Lung Tumors by Agents using Concurrent and Sequential Treatment
    Michael A Pereira; Fiscal Year: 2010
    ..Lung tumors will be induced by NNK and one week later (Week 4), the mice will receive bexarotene, SAHA, sulindac or binary combinations of the agents. There will be two treatment periods;Weeks 4-28, and Weeks 28-50...
  32. Chemoprevention of Tobacco Related Cancer in Animals
    Michael Pereira; Fiscal Year: 2004
    ..budesonide and the farnesyl transferase inhibitor, R115777 in the lung studies and budesonide, ketoprofen and sulindac in the bladder study...
  33. DIETARY PLANT PHENOLICS--EFFECT ON COLONIC BIOMARKERS
    STEVEN SHIFF; Fiscal Year: 1999
    ..a controlled metabolic diet and one of the plant phenolic compounds: curcumin, rutin, or quercetin; or the NSAID sulindac. Serial colon mucosal biopsies will be taken from the volunteers in order to determine the effect of these ..
  34. BIOADHESIVE MICROSPHERES FOR COLON CANCER THERAPY
    NEJAT EGILMEZ; Fiscal Year: 2002
    ..Following their loading with either sulindac (a nonsteroidal anti-inflammatory drug with antitumor activity) and/or Interleukin-12 (a potent immunostimulatory ..
  35. BIODEGRADABLE DELIVERY SYSTEM FOR NSAIDS
    ARTHUR TIPTON; Fiscal Year: 1990
    ..Five NSAIDs will be individually evaluated in the release system: naproxen, diclofenac, piroxicam, sulindac and flurbiprofen...
  36. Characterization of a novel ER membrane protein SPOC
    Ying Huang; Fiscal Year: 2005
    ..Thapsigargin and sulindac sulfide are known to perturb intracellular Ca2+ homeostasis by promoting ER Ca2+ pool depletion...
  37. Characterization of a novel nuclear Rab protein
    Ying Huang; Fiscal Year: 2007
    ..expression is down-regulated by apoptosis inducing agents such as ultraviolet radiation (UV), thapsigargin and sulindac sulfide...
  38. Enhanced Killing of Cancer Cell by Sulindac and Oxidative Stress
    Herbert Weissbach; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenases (COX) 1 and 2...
  39. Planning a Trial of Sulindac for Oral Leukoplakia
    Jay Boyle; Fiscal Year: 2005
    Funding is requested to plan a multi-center, randomized, double-blind, placebo-controlled chemoprevention trial of sulindac for oral leukoplakia through an international collaboration between Memorial Sloan-Kettering Cancer Center (MSKCC) ..
  40. PRECLINICAL EVALUATION OF INTERMEDIATE ENDPOINTS
    BAHARA REDDY; Fiscal Year: 2000
    ..mice will be taken at various time points either from control animals or animals treated with curcumin, rutin, sulindac or high Calcium high vitamin D...
  41. 'IN VITRO SCREENING OF SELECTED CHEMOPREVENTIVE AGENTS U
    David McCormick; Fiscal Year: 2000
    ..Four chemopreventive compounds belonging to the class of antiproliferative agents, 4 HPR, DFMO, Sulindac, and Perillyl Alcohol are being used at five doses in a nontoxic range...
  42. Phase II Study of Sulindac in Oral Premalignant Lesions
    Jay Boyle; Fiscal Year: 2006
    ..trial is a phase II randomized, double-blind, placebo-controlled chemoprevention pilot trial of 150 mg bid sulindac for 6 months for oral premalignant lesions (OPL)...
  43. Death receptors in prostate cancer biology and apoptosis
    M Sheikh; Fiscal Year: 2002
    ..Preliminary results presented in this proposal indicate that sulindac sulfide, a clinically relevant NSAID, induces apoptosis in human prostate cancer cells...
  44. Intestinal Cancer Chemoprevention: Molecular Mechanisms
    Wancai Yang; Fiscal Year: 2009
    ..of a single p2iWAF1/clp1 allele was sufficient to both enhance tumor formation and eliminate the ability of sulindac to inhibit tumor formation (Yang et al, Cancer Res, 61, 565, 2001 a;Yang et al, Cancer Res. 61, 6297, 2001 b)...
  45. EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS IN ANIMAL MOD
    Lee Wattenberg; Fiscal Year: 2000
    ..of four chemopreventive agents including: difluoromethylornithine (DFMO) (aerosol), zileuton (diet and aerosol), sulindac, and combinations of DFMO and budesonide, and sulindac and budesonide to inhibit lung cancer in this model...
  46. Spectral and nano/microscale markers of colon neoplasia
    Vadim Backman; Fiscal Year: 2004
    ..to detect alterations in key signatures by an established non-steroidal anti-inflammatory chemopreventive agent, sulindac. Our future directions would be to use this data to develop an instrument that could assess rectal mucosa LSS to ..
  47. Gordon Research Conference of Polyamine
    Eugene Gerner; Fiscal Year: 2005
    ..abstract_text> ..
  48. APOPTOSIS IN COLON CANCER CHEMOPREVENTION
    Eugene Gerner; Fiscal Year: 2005
    ..abstract_text> ..
  49. Modulation of carcinogen-metabolizing enzyzmes by sulindac
    Henry Ciolino; Fiscal Year: 2008
    ..One promising colon chemopreventive agent is sulindac, a non-steroidal anti-inflammatory drug (NSAID) routinely prescribed to alleviate chronic pain and inflammation...
  50. Nutritional mechanisms and intestinal tumorigenesis
    Leonard Augenlicht; Fiscal Year: 2009
    ....
  51. FATTY ACID MODULATION OF COLON CELL TRANSFORMATION
    Leonard Augenlicht; Fiscal Year: 2008
    ..experiments to confirm and extend these data, including comparative responses to 1,25-dihydroxyvitamin D3 and sulindac, as well as in spontaneous differentiation along the absorptive or secretory cell lineage, we will determine the ..
  52. MOLECULAR CLASSIFICATION OF COLON TUMORS
    Leonard Augenlicht; Fiscal Year: 2004
    ..abstract_text> ..
  53. Modulation of Intestinal Tumorigenesis
    Leonard Augenlicht; Fiscal Year: 2006
    ..We will pursue the p21 gene dosage effect on tumor formation and response to sulindac that we reported...
  54. SITE SPECIFICITY OF GASTROINTESTINAL TUMORIGENESIS
    Leonard Augenlicht; Fiscal Year: 2004
    ..This application focuses on mechanisms regulating the ability of sulindac, an NSAID to stimulate the formation of large bowel tumors in the Apc1638, ApcMin, and ApcMlh1 mouse models, even ..
  55. CURCUMIN--MECHANISMS OF CHEMOPREVENTION
    Leonard Augenlicht; Fiscal Year: 2001
    The mechanism by which curcumin inhibits gastrointestinal tumorigenesis appears to be similar to that of sulindac, a NSAID chemopreventive agent which is highly effective in causing regression of polyps in familial polyposis patients...
  56. Chemoprevention of Oral Cancer with BBIC
    Frank Meyskens; Fiscal Year: 2007
    ..abstract_text> ..
  57. PanAmerican Society for Pigment Cell Research (PASPCR)
    Frank Meyskens; Fiscal Year: 2004
    ..abstract_text> ..
  58. Phase III Colon Cancer Prevention Trial
    Frank Meyskens; Fiscal Year: 2006
    ..double-blind placebo-controlled phase III clinical chemoprevention trial of the combination of DFMO plus sulindac to decrease the rate of new adenomatous polyp formation. 2...
  59. Aberrant Crypt Foci as a Biomarker for Chemoprevention
    Frank Sinicrope; Fiscal Year: 2009
    ..in animal models of colon cancer indicate that ACF can serve as a SEB for chemopreventive efficacy and the NSAID sulindac was shown to regress ACF in Japanese subjects. To date, limited data are available on ACF in the U.S...